Ovid Therapeutics Inc (NASDAQ:OVID)
| 2.50 Delayed Data As of 3:59pm ET |  +0.11 / +4.60%Today’s Change | 1.41 Today|||52-Week Range 3.55 | +34.41% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $171.2M |
Company Description
Ovid Therapeutics, Inc. is a biopharmaceutical company, engaged in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
Contact Information
Ovid Therapeutics, Inc. 1460 Broadway New York New York 10036 |
Employees
Shareholders
| Mutual fund holders | 7.84% |
| Other institutional | 44.11% |
| Individual stakeholders | 30.90% |
Top Executives
| Jeremy Max Levin | Chairman, President & Chief Executive Officer |
| Jason Tardio | Chief Operating Officer |
| Jeffrey A. Rona | Chief Financial & Business Officer |
| Claude Nicaise | Head-Research & Development |
| Julia Tsai | Senior VP-Clinical Development & Medical Affairs |
